Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs). Abstract #1872

Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug
Aim(s): We aimed to identify distinctive genomic alterations associated with benefit from SU and/or EVE treatment in patients with pNETs, by comparing ER to PO. Pts who achieved an objective radiological response together with those with a progression-free survival (PFS) beyond the median reported in the landmark trials were included in the ER group. Pts with a similar PFS to the placebo groups in the pivotal trials were classified as PO.
Materials and methods: Thirty-one pts were screened; following review of availability of the formalin-fixed paraffin embedded (FFPE) samples, 12 were found eligible to proceed with DNA extraction and sequencing. Paired DNA extracted from tumour (T) and non-T or blood was obtained. Two cases did not pass the quality check threshold for variant calling analysis (VCA).
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr. Jorge Barriuso

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1702 Comparative Retrospective Analysis of pNETs Treatment with Everolimus (E) and Sunitinib (S).
Introduction: Two targeted compounds are validated for treatment of pNETs – E and S.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Vera Gorbunova
#1813 Determination of an Optimal Response Cut-Off to Predict Progression-Free Survival(PFS) in Patients(pts) with Well-Differentiated Advanced Pancreatic Neuroendocrine Tumours(pNETs) Treated with Sunitinib(S): An Alternative to the Current RECIST-Response
Introduction: Sunitinib prolongs PFS in pNET; RECIST defined-partial responses (PR; ≥30% decrease) are low.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Angela Lamarca
Keywords: sunitinib, RECIST, cut-off
#1014 Sunitinib Induced Hypocalcaemia During Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor used for pNET treatment.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Krystallenia Alexandraki
#2235 Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)
Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: PhD Paula Jimenez-Fonseca
#1240 Targeted Therapies as First Line Option in Very Advanced Unresectable Pancreatic Neuroendocrine Tumors
Introduction: Neuroendocrine tumors are an entity of rare, heterogeneous group of tumors that can arise from different sites within the body. Although number of different treatment types and modalities exist, chemotherapy remains as the first line option in the management of advance pancreatic NETS (pNETS); two targeted therapies, sunitinib and everolimus remains available only for second line and beyond in Canada.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Young Soo Rho
Authors: Rho Y S, Gilabert M, McLean J, Kavan P, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.